Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 19 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the 2010 Citi Annual Global Health Care Conference on Wednesday, May 26, 2010 at 2:00 p.m. ET at the Hilton hotel, New York City and at the Jefferies 2010 Global Life Sciences Conference on June 10, 2010 at 4:00 p.m. ET at the Grand Hyatt hotel, New York City.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived replay will be available on the Idenix website for two weeks following the conference.  

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to

Idenix Pharmaceuticals Contact:

Teri Dahlman (617) 995-9905

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
2. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
6. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
7. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
8. Idenix Pharmaceuticals Reports First Quarter Financial Results
9. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... today that it has closed the sale of its ... Guerbet (GBT- NYSE Euronext) in a transaction valued at ... manufacturing facilities and a total of approximately 1,000 employees ... St. Louis area. This entire ...
(Date:11/26/2015)... , November 26, 2015 ... --> Accutest Research Laboratories, a ... Research Organization (CRO), has formed a ... Center - Temple Health for joint ... ,     (Photo: ) , ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):